San Luis Wealth Advisors LLC Takes $112,000 Position in Eli Lilly and Company (NYSE:LLY)

San Luis Wealth Advisors LLC acquired a new stake in Eli Lilly and Company (NYSE:LLYGet Rating) in the 1st quarter, HoldingsChannel.com reports. The fund acquired 405 shares of the company’s stock, valued at approximately $112,000.

Other institutional investors have also modified their holdings of the company. Icapital Wealth LLC acquired a new stake in shares of Eli Lilly and in the first quarter valued at $28,000. AllSquare Wealth Management LLC purchased a new stake in shares of Eli Lilly and during the fourth quarter valued at $28,000. HWG Holdings LP purchased a new stake in shares of Eli Lilly and during the fourth quarter valued at $28,000. Leverty Financial Group LLC purchased a new stake in shares of Eli Lilly and during the fourth quarter valued at $29,000. Finally, Selective Wealth Management Inc. purchased a new stake in shares of Eli Lilly and during the first quarter valued at $33,000. Institutional investors and hedge funds own 82.75% of the company’s stock.

Eli Lilly and Stock Performance

NYSE:LLY traded up $5.63 during mid-day trading on Wednesday, hitting $315.94. 6,767 shares of the company’s stock traded hands, compared to its average volume of 2,584,828. The firm has a 50 day moving average of $315.62 and a two-hundred day moving average of $292.52. Eli Lilly and Company has a 12 month low of $220.20 and a 12 month high of $335.33. The firm has a market capitalization of $300.20 billion, a price-to-earnings ratio of 49.49, a price-to-earnings-growth ratio of 2.14 and a beta of 0.35. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 1.70.

Eli Lilly and (NYSE:LLYGet Rating) last posted its earnings results on Thursday, August 4th. The company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.86 by ($0.61). The company had revenue of $6.49 billion for the quarter, compared to the consensus estimate of $6.85 billion. Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. Eli Lilly and’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the business earned $1.87 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 7.96 earnings per share for the current fiscal year.

Eli Lilly and Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 9th. Investors of record on Monday, August 15th will be paid a dividend of $0.98 per share. The ex-dividend date is Friday, August 12th. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.24%. Eli Lilly and’s dividend payout ratio (DPR) is presently 62.52%.

Analyst Ratings Changes

LLY has been the subject of several analyst reports. SVB Leerink initiated coverage on Eli Lilly and in a report on Monday, May 23rd. They set an “outperform” rating and a $341.00 target price for the company. Wells Fargo & Company upped their target price on Eli Lilly and from $280.00 to $305.00 in a report on Friday, April 29th. UBS Group increased their price objective on Eli Lilly and to $335.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 27th. Barclays increased their price objective on Eli Lilly and from $333.00 to $355.00 and gave the stock an “overweight” rating in a research note on Thursday, July 7th. Finally, Mizuho increased their price objective on Eli Lilly and from $315.00 to $356.00 in a research note on Monday, May 2nd. Three research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, Eli Lilly and presently has a consensus rating of “Moderate Buy” and an average price target of $317.00.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 89,458 shares of the business’s stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $332.85, for a total value of $29,776,095.30. Following the sale, the insider now directly owns 103,875,441 shares in the company, valued at $34,574,940,536.85. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, major shareholder Lilly Endowment Inc sold 89,458 shares of Eli Lilly and stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $332.85, for a total value of $29,776,095.30. Following the sale, the insider now owns 103,875,441 shares of the company’s stock, valued at $34,574,940,536.85. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $313.44, for a total value of $313,440.00. Following the transaction, the chief accounting officer now directly owns 6,274 shares in the company, valued at approximately $1,966,522.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,114,591 shares of company stock worth $355,690,328. Corporate insiders own 0.12% of the company’s stock.

About Eli Lilly and

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.